Company news
Xbiotech Inc. (NASDAQ:XBIT) news
Xbiotech Inc. news releases on 6ix. Latest, Jun 15, 2026: XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial…
Press releases & updates
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
June 15, 2026
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
June 17, 2024
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
January 3, 2024
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
September 25, 2023
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
August 29, 2023
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
August 7, 2023
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients
May 21, 2023
XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares
May 16, 2023
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
April 16, 2023
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer
October 12, 2022
XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study
June 19, 2022
XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer
April 27, 2022
XBiotech Inks Clinical Manufacturing Deal
February 1, 2022
XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ
January 25, 2022
FDA Approves XBiotech’s IND in Rheumatology
December 12, 2021
XBiotech to Launch Novel Candidate Therapy for Stroke
October 27, 2021
Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech’s Natrunix™ Anti-Cancer Therapy in Pancreatic Cancer
September 7, 2021
XBiotech Announces Addition of Dr. Mark Ziats, M.D. Ph.D. as Medical Director
August 29, 2021
XBiotech Announces Payment of Dividend to Holders of Common Stock
July 29, 2021
XBiotech Announces Dividend to Holders of Common Stock
July 5, 2021
XBiotech Announces Receipt of $75 Million from Sale of Antibody
June 29, 2021
XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer
June 22, 2021
French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer
May 2, 2021
FDA Gives Go-Ahead for XBiotech’s Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer
April 18, 2021
XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain
January 20, 2021
XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy
January 18, 2021
XBiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-COVID-19 Therapeutic Cocktail
November 18, 2020
XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-Infections
September 20, 2020
XBiotech-Developed COVID-19 Test Supports Convalescent Blood Treatments Now Approved Under FDA Emergency Use Authorization
August 23, 2020
XBiotech Discovers COVID-19 Candidate Therapy
August 16, 2020
XBiotech Achieves Milestone for Production of its New Potential Blockbuster Anti-IL-1⍺ Therapy
July 21, 2020
XBiotech Announces Discovery that Blocking Interleukin-1a Reduces Brain Injury and Neurological Deficit After Stroke
July 13, 2020
XBiotech Identifies “Super Bloods” for the Development of a True Human™ COVID-19 Therapy
April 30, 2020
XBiotech Developing Novel True Human Antibody Targeting Interleukin-1alpha (IL-1⍺)
April 13, 2020
XBiotech and BioBridge Global Collaborate on FDA Program to Develop Potential COVID-19 Treatment Based on Natural Antibodies from Recovered Patients
April 2, 2020
XBiotech Announces Preliminary Results of Tender Offer
February 12, 2020
Corrected Press Release: XBiotech Announces Preliminary Results of Tender Offer
February 12, 2020
XBiotech Commences Tender Offer to Purchase up to $420,000,000 of its Shares
January 13, 2020
XBiotech Closes on Sale of True Human Antibody Bermekimab to Janssen
December 29, 2019
XBiotech Added to NASDAQ Biotechnology Index
December 16, 2019
XBiotech Announces Agreement to Sell True Human Antibody Bermekimab Targeting IL-1a to Janssen
December 6, 2019
XBiotech Announces Rapid Enrollment for its Randomized Multi-Center Clinical Study for Bermekimab in Patients with Hidradenitis Suppurativa
November 18, 2019
XBiotech Announces First Patient Enrolled in Placebo-Controlled Clinical Study Evaluating Its anti-IL-1⍺ Therapy Bermekimab in Patients with Atopic Dermatitis (Eczema)
November 11, 2019
XBiotech Announces First Patient Enrolled in Randomized Multi-Center Clinical Study Evaluating Bermekimab Therapy in Patients with Hidradenitis Suppurativa
October 22, 2019
XBiotech Announces First Patient in Clinical Study to Evaluate Bermekimab in Systemic Sclerosis
October 1, 2019
XBiotech Announces Oral Presentation of Atopic Dermatitis Results for Bermekimab at 2019 EADV Congress in Madrid, Spain
September 26, 2019
XBiotech Announces Granting of Canadian Patent for Treatment of Dermatological Pathologies
September 19, 2019